Comparison · NCT03743051-sae
100 mg Anamorelin HCl vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 100 mg Anamorelin HCl vs Placebo: serious adverse events. Trial comparisons, record NCT03743051-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03743051-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.27 | 0.207 | 0.344 | wilson | |
| Risk in group 2 | 0.245 | 0.185 | 0.318 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0252 | -0.0708 | 0.121 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.1 | 0.759 | 1.6 | log | |
| Odds ratio, group 1 over group 2 | 1.14 | 0.69 | 1.89 | log | |
| Number needed to harm, for one more participant with a serious adverse event on 100 mg Anamorelin HCl than on Placebo | 39.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 100 mg Anamorelin HCl | 100 mg anamorelin HCl (administered as film-coated tablets in fasted condition) was to be taken orally once daily for a total of 24 weeks | 43 | 159 | EG000 |
| Group 2 | Placebo | Placebo (administered as matching placebo tablets in fasted condition) was to be taken orally once daily for a total of 24 weeks | 39 | 159 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events (AEs) were collected from the time of Informed Consent signature through Day 183 (+3) days post study drug administration on Day 1.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1
- NCT number
- NCT03743051
- Phases
- PHASE3
- Conditions
- Cachexia; Cancer, Non Small Cell Lung Cancer
- Interventions
- Anamorelin Hydrochloride, Placebo Oral Tablet
- Lead sponsor
- Helsinn Healthcare SA
- Results first posted
- 2024-06-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03743051?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03743051-sae